Clinical trial
A Phase 2, Proof-of-concept, Placebo Controlled, Randomized, Multi-centre, Double Blind Study of ZYIL1 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT05981040 is registered in ClinicalTrials.gov with Zydus Lifesciences Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Proof-of-concept, Placebo Controlled, Randomized, Multi-centre, Double Blind Study of ZYIL1 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Zydus Lifesciences Limited
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 9, 2023
- Completion date
- June 26, 2024
- Enrollment
- 24 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.